Add to Your Calendar
In this session, we return to TriPaw Therapeutics’ hypothetical prescription drug for canine obesity. After post-marketing adverse events led FDA to issue a “Dear Veterinarian” letter and require updated labeling, TriPaw faced a putative class action claiming it failed to warn pet owners about side effects. Using this scenario, we will examine strategies for early motion practice, defenses against failure-to-warn claims, and broader lessons for companies developing innovative animal health therapeutics.